Verona Pharma plc Verona Pharma To Announce Financial Results For First Quarter Ended March 31, 2019 And Provide Clinical Dev...

 
TIDMVRP 
 
   LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, announces that it will report 
its audited financial results for the first quarter ended March 31, 2019 
on Tuesday, May 7, 2019. 
 
   Verona Pharma will host an investment community conference call at 8:00 
a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) on Tuesday, 
May 7, 2019 to discuss the first quarter financial results and provide a 
clinical development update. 
 
   Analysts and investors may participate in the conference call by 
utilizing the conference ID: 13689539 and dialing the following numbers: 
 
 
   -- 877-423-9813 or 201-689-8573 for callers in the United States 
 
   -- 0800 756 3429 for callers in the United Kingdom 
 
   -- 0800 182 0040 for callers in Germany 
 
 
   Those interested in listening to the conference call live via the 
internet may do so by visiting the "Investors" page of Verona Pharma's 
website at 
https://www.globenewswire.com/Tracker?data=f3h0sQX8AmiO06O9J9dutZ8R-pXOw4-pKnHsvFd-AUY8-0gLCA-UCprX8Lgtr03VYfXM5dTeWeSVV20Mus2y_fRH99TpBbXCLB1wqKHvkJc= 
www.veronapharma.com and clicking on the "Events and presentations" 
link. 
 
   A webcast replay of the conference call (audio) will be available for 30 
days on the "Investors" page of Verona Pharma's website at 
https://www.globenewswire.com/Tracker?data=f3h0sQX8AmiO06O9J9dutYjKAxqzKGvFWEWWdtnmNb4p-_nOZABHHze3EsSiaWCx_iGYawUVC-4k2nsffFzDuSIuVpIIHGL59z7yrxbwPwo= 
www.veronapharma.com. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, 
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that 
has been shown to act as both a bronchodilator and an anti-inflammatory 
agent in a single compound. Ensifentrine is currently in Phase 2b 
clinical development for the maintenance treatment of COPD and is 
planned to enter Phase 3 trials for this indication in 2020. Verona 
Pharma is also developing ensifentrine for the treatment of cystic 
fibrosis and asthma. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements, 
including, but not limited to, statements that there is an opportunity 
for additional bronchodilator and symptomatic improvement via the novel 
mechanism of action of ensifentrine and Verona Pharma's plans to carry 
out further long-term clinical studies of ensifentrine as an add-on to 
both single and dual bronchodilator therapy and the expectation that 
even more profound anti-inflammatory effects, leading to improvements in 
lung function, as well as improvements in symptoms will result. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, the 
following: our limited operating history; our need for additional 
funding to complete development and commercialization of ensifentrine, 
which may not be available and which may force us to delay, reduce or 
eliminate our development or commercialization efforts; the reliance of 
our business on the success of ensifentrine, our only product candidate 
under development; economic, political, regulatory and other risks 
involved with international operations; the lengthy and expensive 
process of clinical drug development, which has an uncertain outcome; 
serious adverse, undesirable or unacceptable side effects associated 
with ensifentrine, which could adversely affect our ability to develop 
or commercialize ensifentrine; potential delays in enrolling patients, 
which could adversely affect our research and development efforts; we 
may not be successful in developing ensifentrine for multiple 
indications; our ability to obtain approval for and commercialize 
ensifentrine in multiple major pharmaceutical markets; misconduct or 
other improper activities by our employees, consultants, principal 
investigators, and third-party service providers; material differences 
between our "top-line" data and final data; our reliance on third 
parties, including clinical investigators, manufacturers and suppliers, 
and the risks related to these parties' ability to successfully develop 
and commercialize ensifentrine; and lawsuits related to patents covering 
ensifentrine and the potential for our patents to be found invalid or 
unenforceable. These and other important factors under the caption "Risk 
Factors" in our Annual Report on Form 20-F filed with the Securities and 
Exchange Commission ("SEC") on March 19, 2019, and our other reports 
filed with the SEC, could cause actual results to differ materially from 
those indicated by the forward-looking statements made in this press 
release. Any such forward-looking statements represent management's 
estimates as of the date of this press release. While we may elect to 
update such forward-looking statements at some point in the future, we 
disclaim any obligation to do so, even if subsequent events cause our 
views to change. These forward-looking statements should not be relied 
upon as representing our views as of any date subsequent to the date of 
this press release. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                          Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer               info@veronapharma.com 
 Victoria Stewart, Director of Communications 
 
N+1 Singer (Nominated Adviser and UK Broker)               Tel: +44 (0)20 7496 3000 
 Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) 
 Mia Gardner (Corporate Broking) 
 
ICR, Inc. (US Media and Investor enquiries) 
Darcie Robinson                                            Tel: +1 203-919-7905 
                                                            Darcie.Robinson@icrinc.com 
Stephanie Carrington                                       Tel. +1 646-277-1282 
                                                            Stephanie.Carrington@icrinc.com
(END) Dow Jones Newswires
May 01, 2019 02:00 ET (06:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024